DARZALEX FASPRO

Trials studying DARZALEX FASPRO

• phase1A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myelomanot yet recruitingn=258
• phase2ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myelomanot yet recruitingn=160
• phase4Home Based Daratumumab Administration for Patients With Multiple Myelomacompletedn=20
• phase2Teclistamab-Daratumumab in AL Amyloidosisrecruitingn=25
• phase2Daratumumab in HLA Desensitization Prior to Transplantationenrolling by invitationn=10
• phase2Daratumumab for Polyneuropathy Associated With MGUSwithdrawn
• EP1Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodiesrecruitingn=8
• phase3A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myelomarecruitingn=486